Header Logo

Connection

RACHEL SCHIFF to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications RACHEL SCHIFF has written about Breast Neoplasms.
RACHEL SCHIFF
Connection Strength
11.531
Breast Neoplasms
  1. HER2-Positive Breast Cancer Treatment and Resistance. Adv Exp Med Biol. 2025; 1464:495-525.
    View in: PubMed
    Score: 0.410
  2. Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic. Endocrinology. 2022 01 01; 163(1).
    View in: PubMed
    Score: 0.333
  3. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882.
    View in: PubMed
    Score: 0.313
  4. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020 04; 17(4):233-250.
    View in: PubMed
    Score: 0.289
  5. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745.
    View in: PubMed
    Score: 0.286
  6. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
    View in: PubMed
    Score: 0.270
  7. Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine. Cancer Discov. 2018 11; 8(11):1352-1354.
    View in: PubMed
    Score: 0.267
  8. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
    View in: PubMed
    Score: 0.250
  9. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
    View in: PubMed
    Score: 0.241
  10. The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer. Curr Oncol Rep. 2017 May; 19(5):35.
    View in: PubMed
    Score: 0.241
  11. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
    View in: PubMed
    Score: 0.232
  12. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
    View in: PubMed
    Score: 0.222
  13. ESR1 mutations?a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015 Oct; 12(10):573-83.
    View in: PubMed
    Score: 0.212
  14. Resistance to Anti-HER2 Therapies in Breast Cancer. Am Soc Clin Oncol Educ Book. 2015; e157-64.
    View in: PubMed
    Score: 0.205
  15. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
    View in: PubMed
    Score: 0.201
  16. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat. 2014 Apr; 144(2):263-72.
    View in: PubMed
    Score: 0.193
  17. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast. 2013 Aug; 22 Suppl 2:S12-8.
    View in: PubMed
    Score: 0.187
  18. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93.
    View in: PubMed
    Score: 0.171
  19. Die and let live: harnessing BikDD to combat breast cancer stem cells. Breast Cancer Res. 2012 May 23; 14(3):310.
    View in: PubMed
    Score: 0.171
  20. ?1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011 Aug 31; 13(4):R84.
    View in: PubMed
    Score: 0.163
  21. More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response. Breast Cancer Res. 2011 Apr 20; 13(2):307.
    View in: PubMed
    Score: 0.159
  22. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62:233-47.
    View in: PubMed
    Score: 0.155
  23. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61.
    View in: PubMed
    Score: 0.155
  24. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.
    View in: PubMed
    Score: 0.150
  25. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501.
    View in: PubMed
    Score: 0.132
  26. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
    View in: PubMed
    Score: 0.129
  27. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
    View in: PubMed
    Score: 0.127
  28. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008 Apr; 29(2):217-33.
    View in: PubMed
    Score: 0.127
  29. The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res. 2007 Dec 01; 13(23):6921-5.
    View in: PubMed
    Score: 0.125
  30. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007 May 02; 99(9):694-705.
    View in: PubMed
    Score: 0.120
  31. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007 Apr 01; 13(7):1950-4.
    View in: PubMed
    Score: 0.120
  32. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006 Dec; 13 Suppl 1:S15-24.
    View in: PubMed
    Score: 0.117
  33. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
    View in: PubMed
    Score: 0.115
  34. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005 Nov; 56 Suppl 1:10-20.
    View in: PubMed
    Score: 0.109
  35. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res. 2005; 7(5):205-11.
    View in: PubMed
    Score: 0.106
  36. Aromatase inhibitors: future directions. J Steroid Biochem Mol Biol. 2005 May; 95(1-5):183-7.
    View in: PubMed
    Score: 0.105
  37. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005 Mar 10; 23(8):1616-22.
    View in: PubMed
    Score: 0.104
  38. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):865s-70s.
    View in: PubMed
    Score: 0.103
  39. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
    View in: PubMed
    Score: 0.101
  40. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35.
    View in: PubMed
    Score: 0.099
  41. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer. Clin Cancer Res. 2024 May 01; 30(9):1889-1905.
    View in: PubMed
    Score: 0.098
  42. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003 Dec; 12(6):362-7.
    View in: PubMed
    Score: 0.095
  43. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
    View in: PubMed
    Score: 0.093
  44. Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res. 2003; 5(5):228-31.
    View in: PubMed
    Score: 0.093
  45. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
    View in: PubMed
    Score: 0.090
  46. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):447S-54S.
    View in: PubMed
    Score: 0.089
  47. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Res. 2022 10 17; 82(20):3673-3686.
    View in: PubMed
    Score: 0.088
  48. Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022 10 01; 40(28):3227-3229.
    View in: PubMed
    Score: 0.086
  49. NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.
    View in: PubMed
    Score: 0.084
  50. Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. Breast Cancer Res Treat. 2021 Nov; 190(2):189-201.
    View in: PubMed
    Score: 0.081
  51. The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells. Dev Cell. 2021 04 19; 56(8):1100-1117.e9.
    View in: PubMed
    Score: 0.079
  52. Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662.
    View in: PubMed
    Score: 0.078
  53. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
    View in: PubMed
    Score: 0.077
  54. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Res. 2020 08 08; 22(1):84.
    View in: PubMed
    Score: 0.076
  55. Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance. Nat Cell Biol. 2020 06; 22(6):701-715.
    View in: PubMed
    Score: 0.074
  56. Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020 Jan 27; 11(1):532.
    View in: PubMed
    Score: 0.073
  57. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2020 Mar; 84:101965.
    View in: PubMed
    Score: 0.073
  58. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
    View in: PubMed
    Score: 0.072
  59. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
    View in: PubMed
    Score: 0.072
  60. In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancer. J Biophotonics. 2020 01; 13(1):e201900180.
    View in: PubMed
    Score: 0.071
  61. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Mol Cancer Res. 2019 11; 17(11):2318-2330.
    View in: PubMed
    Score: 0.071
  62. Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance. Nat Commun. 2019 04 03; 10(1):1522.
    View in: PubMed
    Score: 0.069
  63. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer. 2019 Mar 12; 19(1):220.
    View in: PubMed
    Score: 0.068
  64. AhR ligand aminoflavone suppresses a6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells. J Cell Physiol. 2018 01; 234(1):108-121.
    View in: PubMed
    Score: 0.066
  65. Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. Mol Cancer Ther. 2018 05; 17(5):921-930.
    View in: PubMed
    Score: 0.064
  66. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):279-292.
    View in: PubMed
    Score: 0.064
  67. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERa-GREB1 Transcriptional Axis. Cancer Res. 2018 02 01; 78(3):671-684.
    View in: PubMed
    Score: 0.063
  68. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast. 2017 Aug; 34 Suppl 1:S19-S26.
    View in: PubMed
    Score: 0.061
  69. Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proc Natl Acad Sci U S A. 2017 05 30; 114(22):E4482-E4491.
    View in: PubMed
    Score: 0.060
  70. Identification of MYST3 as a novel epigenetic activator of ERa frequently amplified in breast cancer. Oncogene. 2017 05 18; 36(20):2910-2918.
    View in: PubMed
    Score: 0.058
  71. Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nat Commun. 2016 10 03; 7:12991.
    View in: PubMed
    Score: 0.058
  72. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 11 15; 76(22):6495-6506.
    View in: PubMed
    Score: 0.058
  73. Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint. Mol Cancer Res. 2016 10; 14(10):920-927.
    View in: PubMed
    Score: 0.057
  74. The changing role of ER in endocrine resistance. Breast. 2015 Nov; 24 Suppl 2:S60-6.
    View in: PubMed
    Score: 0.053
  75. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clin Breast Cancer. 2015 Dec; 15(6):448-457.e2.
    View in: PubMed
    Score: 0.053
  76. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
    View in: PubMed
    Score: 0.053
  77. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
    View in: PubMed
    Score: 0.051
  78. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28.
    View in: PubMed
    Score: 0.051
  79. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle. 2015; 14(4):648-55.
    View in: PubMed
    Score: 0.051
  80. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577.
    View in: PubMed
    Score: 0.050
  81. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
    View in: PubMed
    Score: 0.049
  82. Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia. 2014 May; 16(5):390-402.
    View in: PubMed
    Score: 0.049
  83. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med. 2014 Mar 26; 6(229):229ra41.
    View in: PubMed
    Score: 0.049
  84. Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86.
    View in: PubMed
    Score: 0.048
  85. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014 Jan; 124(1):398-412.
    View in: PubMed
    Score: 0.048
  86. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6389-97.
    View in: PubMed
    Score: 0.048
  87. PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. Cancer Cell. 2013 Jun 10; 23(6):753-67.
    View in: PubMed
    Score: 0.046
  88. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97.
    View in: PubMed
    Score: 0.046
  89. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
    View in: PubMed
    Score: 0.045
  90. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(2):531-41.
    View in: PubMed
    Score: 0.043
  91. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.
    View in: PubMed
    Score: 0.041
  92. Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res. 2012 Jan 01; 18(1):118-26.
    View in: PubMed
    Score: 0.041
  93. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18.
    View in: PubMed
    Score: 0.039
  94. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011 Mar 01; 17(5):1147-59.
    View in: PubMed
    Score: 0.039
  95. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10; 29(2):166-73.
    View in: PubMed
    Score: 0.039
  96. Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo. Nano Lett. 2010 Dec 08; 10(12):4920-8.
    View in: PubMed
    Score: 0.039
  97. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol. 2010 Aug; 30(15):3827-41.
    View in: PubMed
    Score: 0.037
  98. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res Treat. 2011 Jan; 125(1):27-34.
    View in: PubMed
    Score: 0.037
  99. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer. 2010 Mar 01; 116(5):1234-42.
    View in: PubMed
    Score: 0.037
  100. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res. 2009 Jul 15; 15(14):4712-21.
    View in: PubMed
    Score: 0.035
  101. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res. 2008; 10(6):R105.
    View in: PubMed
    Score: 0.034
  102. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat. 2009 Sep; 117(2):243-51.
    View in: PubMed
    Score: 0.033
  103. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med. 2007 Sep; 48(9):1501-10.
    View in: PubMed
    Score: 0.031
  104. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006 Aug; 98(3):315-27.
    View in: PubMed
    Score: 0.028
  105. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005 Oct 20; 23(30):7721-35.
    View in: PubMed
    Score: 0.027
  106. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65.
    View in: PubMed
    Score: 0.027
  107. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005 Sep 07; 97(17):1254-61.
    View in: PubMed
    Score: 0.027
  108. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene. 2005 Jun 16; 24(26):4220-31.
    View in: PubMed
    Score: 0.026
  109. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005 Apr 10; 23(11):2469-76.
    View in: PubMed
    Score: 0.026
  110. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
    View in: PubMed
    Score: 0.026
  111. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):327S-330S.
    View in: PubMed
    Score: 0.024
  112. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):331S-6S.
    View in: PubMed
    Score: 0.024
  113. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res. 2003 Sep 01; 63(17):5203-8.
    View in: PubMed
    Score: 0.023
  114. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003 May 15; 63(10):2434-9.
    View in: PubMed
    Score: 0.023
  115. New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):516S-23S.
    View in: PubMed
    Score: 0.022
  116. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.
    View in: PubMed
    Score: 0.022
  117. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s.
    View in: PubMed
    Score: 0.021
  118. A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer. FASEB J. 2021 07; 35(7):e21719.
    View in: PubMed
    Score: 0.020
  119. The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. Biochim Biophys Acta Gene Regul Mech. 2020 11; 1863(11):194631.
    View in: PubMed
    Score: 0.019
  120. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res. 1999 Nov 01; 59(21):5425-8.
    View in: PubMed
    Score: 0.018
  121. Photo activation of HPPH encapsulated in "Pocket" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts. Int J Nanomedicine. 2015; 10:125-45.
    View in: PubMed
    Score: 0.013
  122. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer. Pharmacotherapy. 2013 Oct; 33(10):1126-9.
    View in: PubMed
    Score: 0.011
  123. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70.
    View in: PubMed
    Score: 0.010
  124. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol. 2006 Mar; 20(3):491-502.
    View in: PubMed
    Score: 0.007
  125. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol. 2003 Aug; 17(8):1543-54.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.